Pharmacielo Ltd Total Liabilities

Latest as of September 2025: CA$23.57 Million CAD ≈ $17.05 Million USD

Pharmacielo Ltd total liabilities. Based on the latest financial reports, Pharmacielo Ltd (PCLO) has total liabilities worth CA$23.57 Million CAD (≈ $17.05 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of Pharmacielo Ltd to measure how many days the company can operate on defensive assets alone.

Total Liabilities of Pharmacielo Ltd (2016–2024)

Total liabilities of Pharmacielo Ltd from 2016 to 2024. This chart illustrates how Pharmacielo Ltd's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Pharmacielo Ltd to evaluate the company's liquid asset resilience ratio.

Pharmacielo Ltd Competitors by Total Liabilities

The table below lists competitors of Pharmacielo Ltd ranked by their total liabilities.

Company Country Total Liabilities
DGB Group NV
AS:DGB
Netherlands €14.38 Million
WF Holding Limited Ordinary Shares
NASDAQ:WFF
USA $6.64 Million
Ceres Power Holdings PLC
LSE:CWR
UK GBX38.15 Million
SG COMPANY S.P.A.
F:7KZ
Germany €28.49 Million
TNF Pharmaceuticals, Inc.
NASDAQ:TNFA
USA $5.55 Million
Uma Exports Limited
NSE:UMAEXPORTS
India Rs1.87 Billion
Gafisa S.A
SA:GFSA3
Brazil R$3.20 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Pharmacielo Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PCLO asset base.

Liquidity & Leverage Metrics

Pharmacielo Ltd Total Liabilities Ratios Explained

Pharmacielo Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.15 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.58 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 2.73 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Pharmacielo Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Pharmacielo Ltd (2016–2024)

The table below shows the annual total liabilities of Pharmacielo Ltd from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 CA$25.91 Million
≈ $18.74 Million
+8.10%
2023-12-31 CA$23.97 Million
≈ $17.34 Million
+28.01%
2022-12-31 CA$18.72 Million
≈ $13.54 Million
+12.58%
2021-12-31 CA$16.63 Million
≈ $12.03 Million
-6.45%
2020-12-31 CA$17.78 Million
≈ $12.86 Million
+275.76%
2019-12-31 CA$4.73 Million
≈ $3.42 Million
+20779.39%
2018-12-31 CA$22.66K
≈ $16.39K
+79.19%
2017-12-31 CA$12.64K
≈ $9.15K
-99.23%
2016-12-31 CA$1.65 Million
≈ $1.19 Million
--

About Pharmacielo Ltd

V:PCLO Canada Drug Manufacturers - Specialty & Generic
Market Cap
$6.80 Million
CA$9.40 Million CAD
Market Cap Rank
#27864 Global
#1189 in Canada
Share Price
CA$0.05
Change (1 day)
+0.00%
52-Week Range
CA$0.04 - CA$0.14
All Time High
CA$11.02
About

PharmaCielo Ltd., together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada. The company's products include medicinal-grade dried cannabis flower, cannabis oil extracts, tetrahydrocannabinol and cannabidiol medical cannabis, and other cannabis related products, as well as provides telemedicine software. The company also exports its… Read more